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The presence and transcriptional expression of Epstein–Barr virus (EBV)-encoded genes, oestrogen receptor (ER) status and degree
of lymphocyte infiltration were evaluated in 15 mastectomy-removed breast cancer samples, mostly of ductal origin. With regard to
these parameters, the tumours were heterogeneous. Viral genes, including EBNA1 – a universal EBV marker – and others, selected in
part on the basis of expression in other EBV-associated carcinomas and/or presence in an epithelial cell immortalising subfragment
p31 of viral DNA, were detected in up to 40% of the breast malignancies. The small viral RNAs, EBERs, were not observed. In culture,
p31 EBV DNA, alone among EBV fragments, stimulated the growth of human breast-milk epithelial cells. There was no correlation
between viral and ER expression and tumours were heterogeneous with regard to their invasive lymphocytes: of three studied in
detail, one contained none, another had (mainly) T-lymphocyte aggregates on the tumour periphery, and a third (BC 12) was
infiltrated with both T- and B-lymphocytes. BC 12 differed in several aspects from other malignancies in expressing a transcriptional
activator (BZLF1) associated with overcoming virus latency, and failing to express a viral oncogene, BARF1. Arguments are given for
EBV as a protagonist cocarcinogen in some breast malignancies.
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Breast cancer is well-recognised as a heterogeneous condition and
a major cause of death among women. About 800000 new cases
per year are reported worldwide, with one in 11 women estimated
to develop this malignancy. In developed countries, 4200 cases
per 100000 women per year are seen, 10–15% of these coming
from families with a previous history of breast carcinoma (Parkin
et al, 1999). Breast cancer susceptibility genes, including BRCA 1
and 2 (found on chromosomes-17 and -3), exist, adding support
for genetic predisposition for some forms of this malignancy
(Masood and Kameh, 2002). Late exposure to a common virus,
such as human cytomegalovirus, has been suggested as a risk
factor for breast carcinomas (Richardson, 1997), and Yasui et al
(2001) argue that delayed infection with Epstein–Barr virus (EBV)
may also be a risk for this malignancy. For EBV, there is evidence
for its presence and expression in subpopulations (up to 50%, but
frequently less) of breast tumours (Labrecque et al, 1995; Luqmani
and Shousha, 1995; Bonnet et al, 1999; Joab, 2000; Fina et al, 2001;
Grinstein et al, 2002; Kleer et al, 2002; see the discussion by
Magrath and Bhatia, 1999). Data that illustrate direct entry of this
virus into epithelial cells by routes involving an epithelial-specific
receptor (Sixbey et al, 1987; Yoshiyama et al, 1997) or cell–cell
contact with infected lymphocytes (Bayliss and Wolf, 1980; Speck
and Longnecker, 2000) have been put forward. In one breast
cancer study, the presence of the virus appeared to be associated
with a more malignant phenotype of the tumour (Bonnet et al,
1999).
In another instance, that of gastric carcinoma, where EBV
appears to be associated with a subpopulation (10% or so) of the
tumours, virus presence and expression was found only in the
epithelial cell population (Galetsky et al, 1997). In culture, EBV has
been shown to encode genes capable of growth stimulating
(immortalising) epithelial populations in tissue explants (Griffin
and Karran, 1984; Karran et al, 1990) by a mechanism associated
with telomere survival and ablation of cell senescence (Gao et al,
2002). Based on its well-recognised ability to stimulate cell growth,
and the ubiquitous appearance of this virus in the human
population, it should perhaps not be surprising to find EBV as a
contributing factor to initiation or growth of carcinomas other
than those – notably the head and neck tumour of poorly
differentiated epithelial cells, nasopharyngeal carcinoma (NPC) –
classically associated with it (IARC, 1997).
Whereas with NPC, EBV has been found to be present and
expressed in 100% of the tumours, why only a subset of them
appear to have a viral association is a question that arises with
regard to breast and gastric carcinomas. Arguably, the latter
tumours may be more heterogeneous than NPC. Alternatively,
failure of detection of the virus may reflect low viral loads in the
case of the breast and gastric malignancies, particularly from
economically affluent parts of the world, as compared with high
viral loads in NPCs, generally from less affluent populations.
Further, the role of the virus in malignancy, as exemplified by
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from that in the others. In this study, we were attempting to answer
some of these problems as they apply to breast cancer, by
readdressing the question of EBV gene expression in a sample of
tumours taken by mastectomy from patients in a single British
hospital, over a short period of time, thus minimising other factors
(environment, diet, viral strains, etc.) that might also contribute to
the malignancy. Our data show interesting variations among the
tumours, some of which might be harnessed for therapeutic
purposes.
MATERIALS AND METHODS
Patients
Seventeen tumour biopsy samples were collected, in accordance
with and approval of the local ethics committee, from patients
presenting with suspected breast malignancy to New Cross
Hospital, Wolverhampton, UK, in 1997. Fifteen of these (BCs
1–8, 10–13 and 15–17) were confirmed as breast carcinomas and
two, BCs 9 and 14, not confirmed as such but rather identified as a
cervical lymphadenopathy and a Hodgkin’s disease (HD) tumour,
respectively, were used here as controls. Of the breast carcinomas,
12 were ductal in origin, either grades I (BC 3), II (BCs 1, 5, 6, 11,
12 and 17) or III (BCs 7, 8, 10, 13 and 16). Of the others, BC 2 was a
poorly differentiated anaplastic lobular cancer (probably grade
III), BC 4 (grade III) showed lobular differentiation but with ductal
elements, and BC 15 (grade I) was a tubulo-lobular carcinoma.
Seven out of 15 of the breast cancers (BCs 3–6, 11, 12 and 15) were
oestrogen receptor (ER) positive and the others were negative. The
median patient age was 62 years. BC 9, the cervical lymphadeno-
pathy, was designated as ’possibly of viral origin’, and BC 14, a
nodular sclerosing HD, had high numbers of Reed Sternberg cells.
For molecular analyses, fresh biopsies were transported on dry ice
to the site of analysis, and stored at  701C. For histochemical
analyses, paraffin blocks were kept at  201C. Other controls used
for this study included a North African NPC (C15) passaged as a
xenograft in nude mice and containing 30 copies of the EBV
genome (Busson et al, 1988), a primary African Burkitt’s
lymphoma (from Xue et al, 2002), Asian NPCs (from Hong Kong)
and numerous EBV-carrying lymphocyte cell lines.
Growth stimulus of human epithelial cells in vitro
Fragments covering the whole of the EBV genome from the
transforming B95-8 strain of virus were transfected in culture into
confluent layers of cells derived from human breast milk by a
standard protocol (Karran et al 1990), and they were left to grow or
senesce. In each case, using duplicate cultures, survival of cells
over time was visualised by staining with Leishman’s reagent.
Growth stimulus was obtained with one subgenomic fragment, p31
DNA. As indicated elsewhere (Gao et al, 2002), this 40kbp
component of EBV DNA includes among its genes those encoding
CST/BART transcripts, which to date have been identified in all
EBV-positive tumours (reviewed in Smith, 2001), and an oncogene,
BARF1, with functional homology to human colony-stimulating
factor (CSF) receptor (Strockbine et al, 1998), a product of the
proto-oncogene, c-fms. Both CST/BARTs and BARF1 are expressed
in EBV-positive nasopharyngeal (Hitt et al, 1989) and gastric (Zur
Hausen et al, 2000 ) carcinomas.
Expression of EBV genes
Viral markers chosen for examination in this study (Figure 2 and
legend) include the small EBV RNAs (EBERs 1 and 2) frequently
used in searches for EBV (Labrecque et al, 1995; Brink et al, 2000),
the EBV nuclear antigen, EBNA1, responsible for viral main-
tenance and found expressed in most or all virally associated
tumours (IARC, 1997), and a variety of other genes associated with
expression in NPC (Hitt et al, 1989; Xue et al, 2000), or associated
with epithelial cell immortalisation in culture (Griffin and Karran,
1984; Karran et al, 1990) or, alternatively, thought to be B-cell
specific (Xue et al, 2000, 2002).
Isolation and amplification of viral DNA and RNA
RNA was extracted from fresh frozen tumours, or cells, and
purified as a pellet, using a standard guanidinium–caesium
chloride method, as described (Xue et al, 2000). DNA was
recovered by dialysing the supernatant from RNA preparations.
For analyses by polymerase chain reaction (PCR for DNA) or
reverse transcriptase PCR (RT–PCR, for RNA), primers and
probes described previously (Xue et al, 2002) were generally
adopted. For EBER1 and EBER2, the primer pairs used,
respectively, were (forward) 50-AGGACCTACGCTGCCCTAGA
and 50-AAAACATGCGGACCACCAGC, and (reverse) 50-CCCTA-
GTGGTTTCGGACACAC and 50-GACAAGCCGAATACCCTTCTC.
Products were confirmed by using as probes radiolabelled 50-
GTTTTGCTAGGGAGGAGACG (for EBER1) and 50-GCTCCG-
GGGGAGGAGAAGAGAG (for EBER2). For the CST/BARTs, the
forward and reverse primers were 50-TGCGCCTGGAAGTTGTAC-
TCCCGGAA and 50-CTACCGCCACGCGTCAGCAAA, respectively,
and the probe was 50-GTCTTTGACCTGGAGGGCATC. For EBNA 1
expression, both the viral Qp (latent) and Cp/Wp (lytic) promoters
were analysed. To avoid possible contamination, nested PCR was
not used. After 39 cycles of amplification, PCR products were
separated by electrophoresis on 1% agarose gels containing
ethidium bromide, and their identities were verified by Southern
blot hybridisation. For IR4 hybridisation, probes from both C15
and Raji sequences were used (Xue et al, 2000).
Immunohistochemical evaluation of markers on breast
cancer tissues
Antibodies to CD45 (leucocyte common antigen), CD3 (T-cell
specific) and CD79a (B-cell specific) (DAKO, Denmark House,
Cambridgeshire) were used in tissue examinations. Sections were
cut from formalin-fixed, paraffin-embedded blocks and incubated
with optimally diluted primary antibody for 60min, washed (3 )
with phosphate-buffered saline (PBS), developed using the DAKO
Duet/HRP system, and visualised with diaminobenzidine (DAB).
Excision of epithelial cell populations from tumour tissue
Blocks of frozen tissue from BC 10 and 11, mounted on freezing
chucks with OCT (Ames) and sectioned at 4mm, were placed on
glass slides, stained with haematoxylin and eosin (H & E), and
microscopically inspected for the presence or absence of
lymphocytes. Total RNA was isolated from excised sections devoid
of lymphocytes and reanalysed by RT–PCR for expression of two
EBV genes, EBNA1 and CST/BARTs (Hitt et al, 1989; Smith, 2001).
RESULTS
Stimulation of growth of human epithelial cells by p31
EBV DNA
Others have shown that breast cancer-derived cell lines can be
infected with EBV (Speck and Longnecker, 2000). We asked
whether a subgenomic fragment of EBV DNA (recombinant
cosmid p31; Griffin and Karran, 1984) – which stimulates epithelial
cells from populations of young New World primate (marmoset)
parotid, kidney and nasopharynx tissues to proliferate indefinitely
in culture (Griffin and Karran, 1984; Karran et al, 1990; Gao et al,
2002) – will likewise stimulate the growth of human breast-milk
epithelial cells (Chang et al, 1982), and whether this property is
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has a role in the genesis and/or growth associated with breast
cancer, then growth stimulation in these primary cell cultures
might result from their transfection by one or more viral
fragments. In this experiment, as shown in Figure 1, only the
p31 EBV subfragment was capable of effecting growth stimulation,
showing that viral genetic information, which induces survival in
other primate epithelial populations, also uniquely stimulates the
growth of human milk-derived epithelial cells.
EBV DNA and gene expression in the breast tumours
Whole-cell DNA taken from the 15 breast carcinoma biopsies, and
controls, were examined for the presence of EBV DNA, using as
viral marker an early gene, LF3, which contains the repetitive IR4
sequence, and is found expressed in many tumours, including
NPCs and Burkitt’s lymphomas (BLs) (Xue et al, 2000, 2002). The
IR4 repeats are present in high copy numbers (ranging from 22 to
33) in different cells and tumours (Xue et al, 2003). By PCR, using
39 cycles of amplification and probes and primers described
elsewhere (Xue et al, 2002), this gene was detected in six out of 15
(40%) of the breast tumours (BCs 1, 4, 10–13) examined (data not
shown). All but one (BC 4) of these tumours were of ductal origin,
and BC 4 had ductal components. Only 50% of the EBV-positive
tumours (BC 4, 11 and 12) carried ERs. The two lobular tumours
among our samples and the other ductal tumours, which included
the only two Grade I malignancies investigated, were negative.
For exploring transcriptional expression of viral genes in the
EBV-positive malignancies, we focused on the CST/BART, LF3/IR4
and BARF1 genes – since these were often found expressed with
high frequency in EBV-associated carcinomas (Hitt et al, 1989; Xue
et al, 2000) – and the membrane functions, LMP1 and 2A,
expressed in some of these malignancies, as well as the gene for the
nuclear antigen, EBNA1, essential for the maintenance of EBV in
cells (IARC, 1997), but expressed at low levels. Expression of other
viral genes, including the small RNAs (EBERs), often observed in
high copy numbers and argued to be diagnostically indicative of
EBV (Brink et al, 2000) – but not found so in other cases
(Takeuchi et al, 1997; Sugawara et al, 1999) – and BZLF1, BHRF1
and BHLF1/IR2 (see legend to Figure 2), were also explored. None
of these gene transcripts (except the EBERs) has been widely used
in previous studies investigating EBV in breast cancers, but from
recent data on other tumours (IARC, 1997; Sugawara et al 1999;
Xue et al, 2000, 2002; Zur Hausen et al, 2000) seemed potentially
appropriate for this purpose.
All the EBV-positive breast cancers (BCs 1, 4, 10–13) were
found to express the CST/BART and LF3/IR4 transcripts (using
protocols that allow for sequence variations, as described in Xue
et al, 2000), and three out of six expressed BARF1. EBNA1
expression was found in the same three out of six tumours; very
low level gene expression, as indicated by work on NPCs (Hitt et al,
1989), probably accounts for the fact that EBNA1, and possibly
BARF1, was not detected in all the tumours. Notably, no
expression of EBERs1 or 2, nor the other viral gene transcripts
analysed, LMP1/2A, BHLF1/IR2 and BHRF1, was identified in any
of these tumours, nor in BC 14, an EBV-positive HD. EBER2
expression was observed, however, in the cervical lymphadeno-
pathy, BC 9, and expression of other viral genes, such as EBER1
and LMP1, was identified in control cells (not shown), indicating
that negative data in the breast cancers did not reflect
methodology problems. BZLF1 was found in one malignancy (BC
12), which was infiltrated with both T- and B lymphocytes (see
below). Data from some of our studies are summarised in a
combined Figure 2, and in Table 1.
When viral gene and ER expression data were compared, there
was no correlation, ruling out hormonal control over EBV
expression in these tumours.
Analysis of invasive lymphocytes in the breast tumour
biopsies
It has been argued by some that invasive, virally infected B
lymphocytes might explain the presence of EBV in breast cancers
(Brink et al, 2000; Chu et al, 2001; McCall et al, 2001). For this
reason, in our molecular analyses (cited above), we largely focused
on viral genes associated with EBV-positive carcinomas, rather
than those drawn from the literature on B cells (summarised in
IARC, 1997). In addition, for reasons of interest and possible
relevance, we examined the status of the EBV-positive tumours
with regard to invasive lymphocytes. Cell morphology in paraffin-
fixed EBV-positive breast cancer sections, BCs 1, 4, 10–13, was
examined by H & E staining, with lymphocyte populations
detected using the leuckocyte common antibody, CD45. In this
study, few if any lymphocytes were observed in the tumour
population in BC 10, whereas in BCs 1, 4, 11 and 13 occasional
lymphoid aggregates, located mainly on the periphery of the
tumours, were observed. An interesting exception was found in BC
12, where heavy lymphoid infiltration was observed in the tumour.
Further, staining studies were carried out on sections to identify
the nature of the lymphocytes, using monoclonal antibodies CD79a
and CD3 to stain B- and T-lymphocyte populations, respectively.
Again, little or no staining was seen in the epithelial cells in BC 10,
using either antibody (not shown), although occasional staining
cells were observed in the stroma (as indicated in Figure 3A,
middle panel at left). In most of the other tumours, except BC 12,
staining showed invasive lymphocyte populations to be mainly of
T-cell origin (CD3
þ/CD79a
 ) (not given). In BC 11, one patch of
intratumour B cells (CD79a
þ), as shown (Figure 3A, middle panel
Figure 1 Growth stimulation of human breast-milk cells by subfragments
of EBV DNA from a recombinant cosmid library (Griffin and Karran, 1984),
made from a transforming strain of the virus, B95-8. One fragment in
particular, p31, has the capacity to rescue epithelial cells in primate biopsies
from senescence in culture (Griffin and Karran, 1984; Karran et al, 1990;
Gao et al, 2002). Cells from long-term milk cultures were visualised with
Leishman’s stain. Only p31 DNA, among fragments from this library, was
found to have the ability to growth stimulate the human epithelial cells, as
shown. In other cases, as well as in control untransfected cultures, only
small clusters of dead or dying cells were observed with time.
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other tumours in containing large numbers of lymphocytes (see
Figure 3B, H & E staining). Most of these were T cells, as shown in
Figure 3B (CD3
þ, at right), although about 5% of them stained
with the B-cell (CD79a) marker (not shown).
EBV gene expression in excised epithelial cells
To refute further the arguments that EBV in human breast cancer
materials merely reflects the possible presence of EBV-positive B
cells in the tumour, we re-examined the status of fresh frozen
samples of BC 10 and 11. First, these were subsectioned and
stained with the relevant antibodies to B- and T-lymphocytes, as
described above. Then, sections where staining showed no or
negligible lymphocyte components were excised (as illustrated in
Figure 3A, bottom panel at left) and used to make fresh RNA. If
invasive lymphocytes had been the source of the EBV gene
expression pattern we previously observed (Figure 2), then
quantitatively the load should be diminished or abolished by their
removal. On re-examining expression of CST/BARTs and EBNA1
in these tumours (Figure 4), however, the data showed that little or
no differences were observed in gene expression between selected
samples and total biopsy (Figure 2) samples, arguing for the
presence of EBV in the tumour cells themselves.
Role of amplification in the detection of EBV gene
expression
In one PCR study (McCall et al, 2001), the importance of
amplification cycles was suggested to be of possible significance
for the detection of EBV in breast cancers. Our data imply that use
of fresh, rather than fixed, sample materials is also a critical factor,
as is the choice of viral genes for analysis. We examined viral load
in different samples by semiquantitative RT–PCR as a contributing
factor in detection, using the CST/BART transcripts observed in all
the tumour materials as a marker. For this study, we chose two
breast tumours with different levels of expression, BC 1 (weak) and
BC 12 (strong) (Figure 2), and the lymphadenopathy (BC 9) and
C15 tumour (both very strong) as controls. Using the same primers
as elsewhere (Figures 2), and scoring as positive band detection by
ethidium bromide staining (as in Figure 2) after 30 cycles of
amplification, expression was detectable in controls only; at 35
cycles, BC 12 was positive; at 40 cycles, expression was also
observed in BC 1. These data (not given) emphasise the low levels
of gene expression in EBV-positive breast tumours in general, and
in some in particular, but do not distinguish among high viral loads
in a few cells only, or very low levels in many. They confirm the
arguments about loads put forward elsewhere (McCall et al, 2001).
DISCUSSION
The herpesvirus EBV, a causative agent for infectious mono-
nucleosis, has been associated with various malignancies with
frequencies that vary from 100% (in poorly differentiated NPC) to
a few percent only (in adenocarcinomas) (IARC, 1997), or, as
recently discussed, up to 45% (nine out of 20) in fibroadenomas
from HIV-positive individuals (Kleer et al, 2002). In some studies,
EBV has been identified as a component of breast cancers
(Labrecque et al, 1995; Luqmani and Shousha, 1995; Bonnet et al,
1999; Fina et al, 2001; Grinstein et al, 2002; Kleer et al, 2002) in up
to 50% of cases examined (Bonnet et al, 1999). Interestingly,
whereas association of EBV with about 10% of human gastric
carcinomas (Shibata and Weiss, 1992; Rowlands et al, 1993;
Galetsky et al, 1997; Takano et al, 1999; Yoshiyama et al, 1997;
Zur Hausen et al, 2000) is accepted as real and meaningful,
the association of this virus with human breast cancer
Figure 2 Analysis of expression of EBV RNA in viral DNA-positive
breast cancer biopsies (BCs 1, 4, 10–13). EBV genes whose transcriptional
expression was monitored include: EBNA1, an essential gene for viral
maintenance; three genes (CST/BART, LF3/IR4 and BARF1) expressed in
other epithelial cell malignancies (Hitt et al, 1989; Xue et al, 2000, 2002);
small viral RNAs (EBERs 1 and 2) of unknown function but frequently
expressed in EBV-associated tumours (Arrand, 2000); BZLF1, an
intermediate-early viral lytic cycle marker; and BHLF1/IR2, not universally
found in carcinomas but often highly expressed in B-cell lymphomas (Xue
et al, 2000). Also analysed, but found negative (and not shown), are viral
membrane proteins, LMP1 and 2A, associated with growth of B cells, and
BHRF1, a viral homologue of Bcl-2 (see IARC, 1997). Biopsies, BCs 1, 4,
10–13, are EBV-positive breast cancers, and, except for BC 4, mostly of
ductal origin; BC 9 was from a cervical lymphadenopathy, clinically
questioned as ’possibly of viral origin’; and BC 14 from an HD. For the latter
two cases, the original designation BC is retained here, although these were
subsequently shown not to be breast carcinomas. Other controls include
NPCs (both of Asian and North African origin) and a xenograft (C15; see
Table 1), a Malawian Burkitt’s lymphoma (BL) and B95-8, a prototype
strain from a mononucleosis patient. In the EBNA 1 assays, expressions
from both latent (Qp) and lytic (Cp/Wp) promoters were analysed. For
IR4/LF3 hybridisation, probes corresponding to sequences in C15 and
Raji were used (Xue et al, 2000). Tracks M contain molecular weight
markers.
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yremains controversial in spite of the well-documented positive
findings, and higher frequencies (reviewed by Magrath and Bhatia,
1999).
Here we have explored the hypothesis that in studies where EBV
has not been identified in breast cancers, either in terms of its
genome or expressed genes, experimental design – which may fail
to allow for low viral loads, or rely on the expression of EBV gene
patterns more appropriately associated with B-cell malignancies –
may be a key factor (Brink et al, 2000; Chu et al, 1998; McCall et al,
2001). Further, the use of fixed archival samples by some
investigators (Gaffey et al, 1993; Horiuchi et al, 1994; Lespagnard
et al, 1995; Chu et al, 1998, 2001; Glaser et al, 1998), rather than
fresh materials, can compound the problem as recovery of nucleic
acids from such materials may be hampered, and fixation can
result in DNA (mutational) damage (Williams et al, 1999). From
the data, it is not clear, moreover, that the small viral RNAs
(EBERs) need be good markers for EBV in this malignancy
(Bonnet et al, 1999), and several studies have relied heavily on
them to define the presence or absence of EBV in breast samples
(Horiuchi et al, 1994; Glaser et al, 1998; Brink et al, 2000).
Moreover, a further factor may account for some discrepancy in
that different histological variants of this malignancy may vary in
their association with EBV. It is notable and of possible relevance
that in two studies on medullary carcinomas, which share many
characteristics of lymphoepithelomas and among the breast
cancers have a generally better prognosis, EBV was not identified
(Gaffey et al 1993; Lespagnard et al 1995). However, these data
were not consistent with that reported elsewhere (Luqmani and
Shousha, 1995). Perhaps, more than anything else, the data on EBV
in breast cancer argue strongly for a larger scale and more
systematic study of this topic than, with one possible exception
(Fina et al, 2001), has been carried out to date.
In our current studies, we have used well-defined fresh biopsy
materials, and focused mainly on viral genes that appear from
other work (Griffin and Karran, 1984; Hitt et al, 1989; Karran et al,
1990; Zur Hausen et al, 2000; Gao et al, 2002) to have relevance for
epithelial cells. We initiated our work by identifying the ability of
one subfragment of EBV DNA (p31), but not others, to stimulate
the growth of human milk epithelial cells in culture (Figure 1).
Then, using two viral genes (CST/BARTs and BARF1) found within
p31 DNA, another (LF3) from the same region of the genome that
has been found expressed in all EBV-associated tumours where it
has been explored to date (Xue et al, 2000; 2003), and the EBNA1
gene required for maintenance of EBV, and others, we made a
detailed investigation of a sample of British breast cancer patients.
The samples were fresh and all came from patients seen in a single
hospital within a short period of time. All were treated by
mastectomy, and most were of Caucasian origin with ductal
carcinomas. In all, 40% (six out of 15) of these were found to carry
the EBV genome and express viral genes. With four viral genes
(CST/BARTs and LF3/IR4 (six out of six positive), and EBNA1 and
BARF1 (three out of six), the data were incontrovertible – although
one would predict that EBNA1 at least is probably expressed in all
these tumours, but below the level of our detection methods. As in
some other cases of carcinoma (Takeuchi et al, 1997; Sugawara
et al, 1999; reviewed by Arrand, 2000), the small viral RNAs,
EBERs, which provide good markers for analysing EBV association
in some other tumours, proved not equally useful for the breast
samples. In some cases, particularly for example that of the tumour
BC 10, with no lymphocyte infiltrates, other viral genes but not
EBERs were expressed. Our data on viral gene expression are
shown in part in Figures 2 and 4, and summarised in Table 1. Data
on lymphocyte infiltration into the tumour populations are given
in Figure 3. We found that in the positive breast samples from a
British population, even in fresh biopsies, EBV expression levels
were low as compared, for example, with those found in Asian
NPCs or African BLs, and required optimisation of techniques for
detection.
In general, the EBV-positive cases were younger (median age 54
years) than their EBV-negative (median age 63 years) counterparts.
In particular, we draw attention to the case of patient BC 12 (aged
33 years), whose tumour was unique among those examined, both
with regard to its viral gene expression pattern and its intense
chronic inflammatory infiltrate. Adjacent normal breast lobules
also showed a similar inflammatory infiltrate, clinically suggestive
of an enhanced host response. Alone among the breast tumours
studied, BC 12 expressed a transcription product associated with
the active spliced version (Figure 2) of one of the intermediate-
early viral genes, BZLF1 (or ZEBRA), that disrupts EBV latency
(Miller, 1990). In the HD, BC 14, studied as a control, a product
possibly from an unspliced transcript of this gene was expressed.
Although it has been suggested that only T lymphocytes invade
epithelial cells (Hayday et al, 2001), and our histology studies
showed that any B cells associated with the breast tumour
populations under investigation lay mainly at their periphery,
uniquely in BC 12 many infiltrates were observed in the tumour.
Although these were mainly T lymphocytes (Figure 3B), there were
B cells among them. Thus, the BZLF1 expression detected in this
particular tumour could have been a product of the invasive
lymphocytes, which in turn provoked an enhanced host response
in the patient. Arguably, as shown recently (Speck and Long-
necker, 2000), EBV-infected lymphocytes may be uniquely capable
of targeting breast epithelial cells. Assuming tumours such as BC
12 to make up a subclass of breast cancers, it would be of
therapeutic relevance to explore whether harbouring a potentially
oncolytic version of EBV can be put to therapeutic use, as
discussed for other viruses (Chiocca, 2002). Of possible relevance
to this suggestion, introduction of the BZLF1 (or a similar EBV
gene) via an adenoviral vector was shown to inhibit the growth of
an NPC xenograft in a mouse model (Feng et al, 2002). Harnessing
endogenous EBV gene expression for therapeutically useful
purposes may thus be worthy of further exploration.
Table 1 EBV gene expression in breast cancer and controls
Breast samples
EBV genes BC 1 BC 4 BC 10 BC 11 BC 12 BC 13 9 14 C 15
BZLF1     +    +
CST (BART) + + + + + + + + +
IR4/LF3 (Raji seq) + + + + + +    
IR4/LF3 (C15 seq) + – + + + +   +
EBNA1 (Qp)   ++  +   +
EBER2       +   +
Negative in breast cancers: EBER1, EBNA1 (Cp/Wp), BHRF1, IR2/BHLF1, LMP1, LMP2A. BC 1¼NHS BSP grade II ductal
carcinoma; BC 4¼mixed pattern carcinoma, ductal elements present; BC 10¼high-grade ductal carcinoma; BC
11¼ductal carcinoma; BC 12¼NHS BSP grade II infiltrating ductal carcinoma; BC 13¼NHS BSP grade III invasive ductal
carcinoma; 9¼cervical lymph node; 14¼HD; C15=NPC xenograft (Busson et al, 1988).
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presented here, we argue that the relevant question(s) now is not
whether EBV can be present and persist in breast carcinomas, but
rather what its role might be. The notion of this virus as a
’harmless’ passenger’ (Labrecque et al, 1995) seems implausible in
view of its association with many malignancies of different cell
types, and the ability of its genes to contribute to cellular growth
(immortalisation) in culture. In a recent comprehensive study of
EBV, it was declared to be ‘carcinogenic to humans’ (IARC, 1997).
Bonnet et al (1999) showed that the more aggressive breast
tumours in their studies were to be found among the EBV-positive
cases. Our data were mainly derived from grade II/III breast
malignancies that were evenly split with regard to their EBV status,
whereas neither of the grade I malignancies available for study
proved to be EBV positive. One of the functions that EBV can
confer upon epithelial cells is to extend their life span, as
illustrated in Figure 1 and elsewhere. In other studies, primary
epithelial cells immortalised by a subfragment of EBV appeared to
lose their viral information (classically called ‘hit and run’
immortalisation), yet did not go through crisis; throughout their
growth cycle their telomeres remained constant in length (Gao
et al, 2002). In recent studies on gastric carcinoma cell lines
(Kassis et al, 2002), the presence of EBV was found to increase cell
motility and mobility. The data overall argue for EBV as a
protagonist with regard to some carcinomas, including breast
cancer, possibly acting as a ‘carcinogenic agent’ that can maintain
telomerase activity in vivo. The virus seems unlikely to be a mere
passenger.
In the newer molecular approaches, transcription profiles and
microarray techniques are being used to modify taxonomies for
breast cancer. For example, Perou et al (2000), using 65 different
surgically removed samples identified great variations in the
patterns of gene expression, with sets of genes (clusters)
contributing to independent patterns. The largest cluster included
expression of genes associated with cellular proliferation. Oestro-
gen receptors were also detected in a cluster. Microarray
technology offers great potential for unravelling some of the
problems associated with breast cancer. In future, it would seem
relevant to adapt it to include EBV gene expression.
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